Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CorMedix Inc (CRMD : NSDQ)

• Company Description    CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrog Number of Employees: 191

• Price / Volume Information    Yesterday's Closing Price: $7.79 Daily Weekly Monthly 20 Day Moving Average: 1,063,158 shares Shares Outstanding: 77.94 (millions) Market Capitalization: $607.19 (millions) Beta: 1.40 52 Week High: $13.02 52 Week Low: $6.13 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.30% 0.63% 12 Week 8.34% 2.19% Year To Date -33.02% -40.89%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 389 INTERPACE PKWY SUITE 450 - PARSIPPANY,NJ 07054 USA ph: 908-517-9500 fax: 908-429-4307 daniel@lifesciadvisors.com http://www.cormedix.com

• General Corporate Information    Officers Joseph Todisco - Chief Executive Officer; Director and Chairman of Susan Blum - Executive Vice President and Chief Financial Offic Myron Kaplan - Director Janet Dillione - Director Gregory Duncan - Director Peer Information CorMedix Inc (CORR.) CorMedix Inc (RSPI) CorMedix Inc (CGXP) CorMedix Inc (BGEN) CorMedix Inc (GTBP) CorMedix Inc (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 21900C308 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 77.94 Most Recent Split Date: 3.00 (0.20:1) Beta: 1.40 Market Capitalization: $607.19 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.54 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 10.00% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: 14.43 Trailing 12 Months: 4.10 PEG Ratio: 1.44 Price Ratios Price/Book: 1.33 Price/Cash Flow: 3.81 Price / Sales: 1.31 EPS Growth vs. Year Ago Period: 3.57% vs. Previous Quarter: -32.56% Sales Growth vs. Year Ago Period: 156.51% vs. Previous Quarter: -20.01% ROE 09/30/26 - - 06/30/26 - 40.52 03/31/26 - 45.57 ROA 09/30/26 - - 06/30/26 - 20.61 03/31/26 - 24.76 Current Ratio 09/30/26 - - 06/30/26 - 2.56 03/31/26 - 2.97 Quick Ratio 09/30/26 - - 06/30/26 - 2.36 03/31/26 - 2.74 Operating Margin 09/30/26 - - 06/30/26 - 36.76 03/31/26 - 40.93 Net Margin 09/30/26 - - 06/30/26 - 40.49 03/31/26 - 45.25 Pre-Tax Margin 09/30/26 - - 06/30/26 - 44.00 03/31/26 - 46.25 Book Value 09/30/26 - - 06/30/26 - 5.87 03/31/26 - 5.57 Inventory Turnover 09/30/26 - - 06/30/26 - 2.49 03/31/26 - 2.29 Debt-to-Equity 09/30/26 - - 06/30/26 - 0.31 03/31/26 - 0.33 Debt-to-Capital 09/30/26 - - 06/30/26 - 23.95 03/31/26 - 24.90

Powered by Zacks Investment Research ©